Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients.

Berns JS, Haghighat A, Staddon A, Cohen RM, Schmidt R, Fisher S, Rudnick MR, Tomaszewski JE.

Cancer. 1995 Aug 1;76(3):497-500.

PMID:
8625132
3.
4.

Progressive glomerular toxicity of ifosfamide in children.

Prasad VK, Lewis IJ, Aparicio SR, Heney D, Hale JP, Bailey CC, Kinsey SE.

Med Pediatr Oncol. 1996 Sep;27(3):149-55.

PMID:
8699991
5.

Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.

Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, Koren G.

J Clin Pharmacol. 1999 May;39(5):454-61.

PMID:
10234592
6.

Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas.

Marina NM, Poquette CA, Cain AM, Jones D, Pratt CB, Meyer WH.

J Pediatr Hematol Oncol. 2000 Mar-Apr;22(2):112-8.

PMID:
10779023
7.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
8.

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.

Talbot SM, Rankin C, Taub RN, Balcerzak SP Jr, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH.

Cancer. 2003 Jul 15;98(2):331-6.

9.

A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.

Ho PT, Zimmerman K, Wexler LH, Blaney S, Jarosinski P, Weaver-McClure L, Izraeli S, Balis FM.

Cancer. 1995 Dec 15;76(12):2557-64.

PMID:
8625085
10.

Long-term evaluation of Ifosfamide-related nephrotoxicity in children.

Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, Bergeron C, Defachelles AS, Gentet JC, Schmitt C, Rubie H, Munzer M, Plantaz D, Deville A, Minard V, Corradini N, Leverger G, de Vathaire F.

J Clin Oncol. 2009 Nov 10;27(32):5350-5. doi: 10.1200/JCO.2008.17.5257. Epub 2009 Oct 13.

PMID:
19826134
11.

End-stage renal interstitial fibrosis in an adult ten years after ifosfamide therapy.

Friedlaender MM, Haviv YS, Rosenmann E, Peylan-Ramu N.

Am J Nephrol. 1998;18(2):131-3.

PMID:
9569955
12.

Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child.

Ashraf MS, Skinner R, English MW, Craft AW, Pearson AD.

Med Pediatr Oncol. 1997 Jan;28(1):62-4.

PMID:
8950339
13.

Tubulointerstitial nephritis following high-dose ifosfamide in three breast cancer patients.

Hill PA, Prince HM, Power DA.

Pathology. 2000 Aug;32(3):166-70.

PMID:
10968388
14.

Renal dysfunctions secondary to ifosfamide treatment in children.

Tokuc G, Yalçiner A, Kebudi R, Dogan S, Görgün O, Ayan I.

J Exp Clin Cancer Res. 1997 Jun;16(2):227-30.

PMID:
9261752
15.

Ifosfamide nephrotoxicity in pediatric cancer patients.

Lee BS, Lee JH, Kang HG, Hahn H, Lee JH, Shin HY, Ha IS, Cheong HI, Ahn HS, Choi Y.

Pediatr Nephrol. 2001 Oct;16(10):796-9.

PMID:
11605785
16.

Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.

Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, Ragab A, Wharam M, Wiener E, Maurer H.

Am J Pediatr Hematol Oncol. 1994 Nov;16(4):286-95.

PMID:
7978043
17.

High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.

Yalcin B, Pamir A, Buyukcelik A, Utkan G, Akbulut H, Demirkazik A, Icli F.

Exp Oncol. 2004 Dec;26(4):320-5.

PMID:
15627067
19.
20.

[Ifosfamide induced encephalopathy: 15 observations].

Dufour C, Grill J, Sabouraud P, Behar C, Munzer M, Motte J, Oberlin O, Paci A, Hartmann O.

Arch Pediatr. 2006 Feb;13(2):140-5. Epub 2005 Dec 20. French.

PMID:
16364615

Supplemental Content

Support Center